Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

Goto, Shinya, Ogawa, Hisao, Takeuchi, Masaru, Flather, Marcus D, Bhatt, Deepak L and , J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. European Heart Journal, 31 (21). pp. 2601-13. ISSN 0195-668X

Full text not available from this repository. (Request a copy)

Abstract

Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).

Item Type: Article
Uncontrolled Keywords: acute coronary syndrome,administration, oral,coronary artery disease,double-blind method,drug-induced liver injury,female,hemorrhage,humans,imines,long qt syndrome,male,middle aged,platelet aggregation inhibitors,pyridines,receptor, par-1
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 20 Jan 2014 16:12
Last Modified: 23 Jan 2019 12:41
URI: https://ueaeprints.uea.ac.uk/id/eprint/46246
DOI: 10.1093/eurheartj/ehq320

Actions (login required)

View Item